A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A

Botulinum toxin type A (commonly referred to as 'Botox') injections are a treatment that dermatologists regularly use to smoothen wrinkles such as 'Crow's feet', to rejuvenate the skin surrounding the eye (the 'periorbital region'). However, botulinum toxin type A can be associated with injection-site bruising that may take up to 2 weeks to heal. Hirudoid, an ointment that is applied to the skin, has been shown to reduce the severity of swelling and bruising after facial cosmetic procedures. The objective of this study is to study the effectiveness of Hirudoid in reducing the severity of bruising following the use of botulinum toxin type A for periorbital rejuvenation of Crow's feet in adult patients. The knowledge gained from this study can help to develop an effective medicated skincare regimen that helps to minimize the complications of botulinum toxin type A and speed up recovery time, which may be of benefit to patients who receive botulinum toxin type A injections for treatment of Crow's feet.

NCT Number	NCT07388927
Lead Sponsor	DKSH Management (Thailand) Limited
Conditions	Ecchymosis After Periorbital Rejuvenation With Botulinum Toxin Type A, Crow's Feet Lines, Lateral Canthal Lines, LCL
Enrollment	48 participants
Start Date	2026-02
Primary Completion	2026-03 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2026-02-05